Agilis Biotherapeutics Sponsors the Friedreich's Ataxia Research Alliance (FARA) Energy Ball in Tampa, FL

Annual Event Raises Millions for Research to Find a Cure for Friedreich's Ataxia (FA)

Cambridge, MA, September 19, 2015--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Agilis was a gold sponsor of the 7th annual FARA Energy Ball in Tampa, Florida. The Tampa community united with scientists and patient families to raise funds to continue research to find a cure for FA. Wendy Ryan, *ABC Action News Anchor*, emceed the event and Tod Leiweke, former Tampa Bay Lightning CEO and current National Football League COO chaired the event with his wife Tara for the fifth consecutive year. There was a live auction featuring exclusive getaways, cocktails and dinner, and a live performance by *Southern Train*. Funds from the event benefited FARA and the USF Ataxia Research Center. Last year, FARA funded over $4 million in drug development and clinical research worldwide.

Friedreich's Ataxia (FA) is a debilitating multi-system disease and the most common cause of inherited ataxia; 1 in 100 people are carriers of the FA Gene. What begins as difficulty with balance and coordination, progresses over a short period of time to a life altering loss of mobility, energy, speech and hearing, robbing children and young adults of the ability to live active and independent lives.

Jennifer Farmer, FARA Executive Director, stated, "When our generous donors, dedicated researchers, pharmaceutical partners and courageous individuals battling FA come together, we facilitate life changing research progress. For more information, visit www.curefa.org/energyball

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's Ataxia, Angelman Syndrome and Fragile X Syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's Ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 people living with Angelman Syndrome in the US. Fragile X Syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809